Free Trial

KalVista Pharmaceuticals Q3 2023 Earnings Report

KalVista Pharmaceuticals logo
$8.47 -0.18 (-2.08%)
(As of 03:34 PM ET)

KalVista Pharmaceuticals Earnings Headlines

KalVista Pharmaceuticals Appoints New COO Amid Strategic Growth
KalVista Pharmaceuticals Appoints New COO Amid Strategic Growth
Why I'm telling friends to avoid gold stocks
Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."
KalVista Pharma Appoints Jeb Ledell As COO
KalVista Appoints Jeb Ledell as Chief Operating Officer
See More KalVista Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like KalVista Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on KalVista Pharmaceuticals and other key companies, straight to your email.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals (NASDAQ:KALV), a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

View KalVista Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings